on TRANSGENE (EPA:TNG)
Transgene and ProBioGen strengthen their partnership with a new licensing agreement
Transgene, a biotechnology company specializing in the development of cancer immunotherapies, is expanding its strategic partnership with ProBioGen, a Berlin-based biologics manufacturer. This agreement concerns the avian cell line AGE1.CR.pIX®, intended to increase Transgene's vaccine production capacity. ProBioGen's technology, recognized for its efficacy and cost-effectiveness, allows Transgene to better prepare for future clinical applications.
The AGE1.CR.pIX® platform offers efficient manufacturing processes, boosting production while ensuring a reliable and reproducible process. Transgene and ProBioGen share a common ambition: to advance personalized medicine through optimized production capabilities.
R. P.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all TRANSGENE news